CohBar to Announce 2019 First Quarter Financial Results and Provide Business Update on May 7, 2019

MENLO PARK, Calif., April 26, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. CWBR, a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that the company will release its first quarter 2019 financial results after the market closes on Tuesday, May 7, 2019.  Management will host a conference call with a slide presentation at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company's business.

Details for the Conference Call and Slide Presentation:



Date: May 7, 2019

Time: 5:00 p.m. ET (2:00 p.m. PT)

Conference Audio

• Dial-in U.S. and Canada: (800) 289-0438
• Dial-in International: (323) 794-2423
• Conference ID No.: 1071020

Slide Presentation

• Go to www.webex.com, click on the ‘Join' button and enter meeting number 924 256 010 and Password CWBR, or
• Go to www.cohbar.com and click on Q1 2019 Shareholder Presentation at top of homepage.

We kindly request that you please call into the conference audio approximately 10 minutes prior to the start time so that we can begin promptly.

An audio replay of the call will be available beginning at 8:00 p.m. Eastern Time on May 7, 2019, through 11:59 p.m. Eastern Time on May 28, 2019. To access the recording please dial (844) 512-2921 in the U.S. and Canada, or (412) 317-6671 internationally, and reference Conference ID# 1071020. The audio replay along with the slide presentation will also be available on the homepage at www.cohbar.com from May 7, 2019 through May 28, 2019.

About CohBar

CohBar CWBR is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar's founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar's efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases with underlying metabolic dysfunction, including nonalcoholic steatohepatitis (NASH), obesity, Type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. To date, the company and its founders have discovered more than 100 MDPs.

For additional company information, please visit www.cohbar.com.

Investor and Media Contact:

Jeff Biunno, CFO

CohBar, Inc.

(650) 446-7888

jeff.biunno@cohbar.com

Joyce Allaire

LifeSci Advisors, LLC

jallaire@lifesciadvisors.com